Efficacy of thymoquinone in the treatment of experimental lipopolysaccharide-induced acute lung injury

Creative Commons License

Colak M., Kalemci S., ÖZGEN ALPAYDIN A., KARAÇAM V., Meteoglu I., YILMAZ O., ...Daha Fazla

KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.17, sa.2, ss.65-69, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5114/kitp.2020.97259
  • Dergi Adı: KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Directory of Open Access Journals
  • Sayfa Sayıları: ss.65-69
  • Anahtar Kelimeler: acute lung injury, thymoquinone, lipopolysaccharide, ACUTE RESPIRATORY-DISTRESS, EUROPEAN CONSENSUS CONFERENCE, NIGELLA-SATIVA, RELEVANT OUTCOMES, DEFINITIONS, PREVENTION, MECHANISMS, MODEL, ARDS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Introduction: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are acute onset syndromes affecting the lungs, which develop for several reasons and are characterized by hypoxemia and diffuse lung infiltration. The activity of thymoquinone (TO) is known in acute lung injury. It is considered that it could be effective in ALI/ARDS treatment by ensuring possible COX-2 inhibition.